Gold prices tick higher on fresh US tariff threats, Fed rate cut hopes
Director Kevin Tang purchased 1,300,000 shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) between August 1 and August 5, 2025. The purchases were made at prices ranging from $10.12 to $11.68, for a total value of $13,590,000. The stock has shown remarkable momentum, delivering a 113% return over the past year. According to InvestingPro data, management’s share purchases align with the company’s strong performance, with the stock currently trading near its 52-week high of $11.48.
The transactions increased Tang’s indirect ownership to 11,329,500 shares. The shares are indirectly owned by Tang Capital Partners (WA:CPAP), LP and Tang Capital Partners International, LP, of which Kevin Tang is the sole manager. With a market capitalization of $1.54 billion and an "GREAT" Financial Health score from InvestingPro, Aurinia shows strong fundamentals. Discover 15 more exclusive ProTips and comprehensive analysis in the Pro Research Report, available with an InvestingPro subscription.
In other recent news, Aurinia Pharmaceuticals reported second-quarter earnings that exceeded analyst expectations, driven by robust sales of its lupus nephritis treatment, LUPKYNIS. The company posted adjusted earnings per share of $0.16, surpassing the analyst estimate of $0.14. Revenue for the quarter reached $70 million, exceeding the consensus estimate of $64.27 million and marking a 22% increase from the $57.2 million reported in the same period last year. Aurinia Pharmaceuticals also raised its full-year revenue guidance, indicating a positive outlook for continued growth. These developments reflect the company’s strong performance and market presence. No recent mergers or acquisitions have been reported. Additionally, there have been no recent analyst upgrades or downgrades for the company. Investors may find these updates noteworthy as they assess Aurinia Pharmaceuticals’ financial health and market trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.